Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.36 |
| ▸ | WNT3A | P56704 | 10/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670591 | 0.89 | FGFR4 (0.42) | FAAHWNT3A | |
| SCHEMBL19365327 | 0.89 | FAAH (0.36) | FAAHWNT3ACYP11B2RPS6KA2MPL | |
| SCHEMBL19670394 | 0.89 | FAAH (0.34) | FAAHRPS6KA2MPL | |
| SCHEMBL19670124 | 0.88 | WNT3A (0.40) | WNT3ACSF1RCYP11B2 | |
| SCHEMBL19670620 | 0.87 | HTR2A (0.38) | WNT3ACYP11B2ABL1 | |
| SCHEMBL12654526 | 0.87 | MPL (0.42) | FAAHMPL | |
| SCHEMBL19670532 | 0.86 | FAAH (0.41) | FAAHWNT3A | |
| SCHEMBL19670435 | 0.85 | WNT3A (0.36) | WNT3ACSF1RCYP11B2ABL1 | |
| SCHEMBL19670352 | 0.84 | HTR2C (0.47) | — | |
| SCHEMBL19365697 | 0.84 | DYRK1A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FAAH 977/4885WNT3A 4291/4885CSF1R 2306/4885 |
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | FAAH 1283/4885WNT3A 4543/4885CSF1R 1955/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | FAAH 977/4885WNT3A 4291/4885CSF1R 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.